Germany - Drugs
For more information and to make a bid you will need to go to the third party website.
Details
Provided by
- Opportunity closing date
- 30 November 2024
- Opportunity publication date
- 21 October 2022
- Category
- 33600000: Ph
- Value of contract
- to be confirmed
- Your guide to exporting
Description
The participating health insurance funds are pursuing the goal of concluding discount contracts with all suitable pharmaceutical companies in accordance with Section 130a (8) SGB V for the active ingredient tiotropium bromide (Spiriva(R) Respimat, ATC: R03BB04). The contract is concluded within the framework of the health insurers' open-house original procedure:Individual negotiations on contract content are not conducted; uniform conditions apply. The health insurers do not guarantee exclusivity to individual contract partners. The contract period is a maximum of 24 months beginning on 01.12.2022. The contract ends on 30.11.2024 at the latest, regardless of the date on which the contract was concluded. In the event of patent expiry before 30.11.2024, the contract shall end automatically at the end of the month of patent expiry. All further information can be found in the participation and contract documents.
Joining this open house original procedure is possible at any time during the contract period. Due to the existence of industrial property rights with regard to the active ingredient covered by the agreement, the participation and contract documents will only be made available to those pharmaceutical companies that offer/market drugs for the active ingredient covered by the agreement or that credibly demonstrate to TK that they intend to offer/market drugs for the active ingredient covered by the agreement within the term of the agreement.A contract will be concluded with all pharmaceutical companies that meet the requirements of Annex 4 to the contract (self-declaration of approval and company) and confirm this in electronic form in accordance with Section 126a of the German Civil Code (BGB).This announcement does not relate to the award of a public contract within the meaning of the Public Procurement Directive (2014/24/EC) or antitrust law. In the interest of providing the broadest possible information to interested pharmaceutical companies, this notice is published in the Supplement to the Official Journal of the European Union. The designation of the procedure "Open Procedure" according to IV.1.1) and the specification of the award criteria according to II.2.5) used in the text of this announcement are due to the requirements of the announcement form and have no further meaning. Neither this nor the use of the "TED" medium is in any way connected with submission to procurement law regulations, the application of which is not mandatory by law or procurement regulations.
- Opportunity closing date
- 30 November 2024
- Value of contract
- to be confirmed
About the buyer
- Address
- Techniker Krankenkasse Bramfelder Str. 140 Hamburg 22305 Germany
- Contact
- dzem@tk.de
Bid for tender
If your company meets the requirements of the tender, go to the website where the tender is hosted and submit your bid.
This website contains links to other websites that we do not control or maintain. We are not responsible for the content of these sites. We provide these links for your convenience only, and do not necessarily endorse their content.
Before entering into a contract you need to apply for any necessary export licences, which can include applications to trade in certain goods. You should also make your own enquiries and be satisfied by the accuracy of any information supplied to you.
This opportunity has been translated from its original language. You should check if you need to apply in the original language.